{"id":170965,"date":"2025-09-05T03:46:33","date_gmt":"2025-09-05T07:46:33","guid":{"rendered":"https:\/\/44.250.171.167\/?p=170965"},"modified":"2025-09-05T03:46:33","modified_gmt":"2025-09-05T07:46:33","slug":"caplin-point-q1-fy26-earnings-results","status":"publish","type":"post","link":"https:\/\/alphastreet.com\/india\/caplin-point-q1-fy26-earnings-results\/","title":{"rendered":"Caplin Point Q1 FY26 Earnings Results"},"content":{"rendered":"<p>Caplin Point Laboratories Ltd is engaged in the manufacturing and sourcing of active pharmaceutical ingredients APIs, finished formulations, research and development, and clinical research. The company has a strong international footprint with significant presence in Latin America, Africa, the USA, and other key markets.<\/p>\n<h2><strong>Q1 FY26 Earnings Summary <\/strong><\/h2>\n<ul>\n<li>Revenue: \u20b9510 crore, up 11.11% year-on-year YoY from \u20b9459 crore in Q1 FY25.<\/li>\n<li>Total Expenses: \u20b9348 crore, up 7.74% YoY from \u20b9323 crore.<\/li>\n<li>Consolidated Net Profit PAT: \u20b9151 crore, up 20.8% YoY from \u20b9125 crore in the same quarter last year.<\/li>\n<li>Earnings Per Share EPS: \u20b920.10, up 23.24% from \u20b916.31 YoY.<\/li>\n<\/ul>\n<h2><strong>Operational &amp; Strategic Update<\/strong><\/h2>\n<ul>\n<li>Revenue Growth: Growth was driven by robust demand across Latin American and African markets, alongside steady contributions from the US generics portfolio.<\/li>\n<li>Cost Control: Expenses increased at a slower pace compared to revenues, reflecting operational discipline and improved sourcing efficiencies.<\/li>\n<li><a href=\"https:\/\/www.bseindia.com\/xml-data\/corpfiling\/AttachHis\/e18ffab4-fe29-41aa-a4b8-a235793e22bf.pdf\" target=\"_blank\" rel=\"noopener\">Profitability Expansion<\/a>: Net profit rose more than 20% YoY as margin improvement came from higher specialty formulations mix and efficient operations.<\/li>\n<li>Business Segments: Finished formulations business remained the primary revenue driver, complemented by steady API sales and rising contract research activity.<\/li>\n<li>Strategic Investments: Continued investments in R&amp;D for specialty injectables and niche products to expand presence in regulated markets.<\/li>\n<li>Global Reach: Strengthened partnerships in Latin America and steady growth across Africa enhanced export momentum.<\/li>\n<\/ul>\n<h2><strong>Corporate Developments<\/strong><\/h2>\n<p>Caplin Point\u2019s <a href=\"https:\/\/www.bseindia.com\/xml-data\/corpfiling\/AttachHis\/e18ffab4-fe29-41aa-a4b8-a235793e22bf.pdf\" target=\"_blank\" rel=\"noopener\">Q1 FY26<\/a> performance reflects a healthy combination of <strong>double-digit revenue growth and strong profit expansion<\/strong>, aided by disciplined execution and a balanced international product portfolio. With effective cost management and sustained demand in export markets, the company has demonstrated resilience in a competitive pharmaceutical environment.<\/p>\n<p><img loading=\"lazy\" decoding=\"async\" class=\"aligncenter size-full wp-image-170966\" src=\"https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2025\/09\/CAPLI.png\" alt=\"CAPLIPOINT Q1 FY26 Earnings Results\" width=\"1489\" height=\"1817\" srcset=\"https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2025\/09\/CAPLI.png 1489w, https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2025\/09\/CAPLI-246x300.png 246w, https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2025\/09\/CAPLI-839x1024.png 839w, https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2025\/09\/CAPLI-768x937.png 768w, https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2025\/09\/CAPLI-1259x1536.png 1259w\" sizes=\"auto, (max-width: 1489px) 100vw, 1489px\" \/><\/p>\n<h2><strong>Looking Ahead<\/strong><\/h2>\n<p>The company aims to enhance its footprint in the United States through expansions in sterile injectables and complex generics, while continuing to focus on Latin America and Africa for stable growth. Investments in R&amp;D, regulatory approvals, and specialty drug launches are expected to solidify earnings momentum in FY26 and beyond.<\/p>\n<p>Explore the company\u2019s past earnings and latest concall transcripts,<a href=\"https:\/\/44.250.171.167\/symbol\/caplipoint\/\"> click here<\/a> to visit the AlphaStreet India News Channel.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Caplin Point Laboratories Ltd is engaged in the manufacturing and sourcing of active pharmaceutical ingredients APIs, finished formulations, research and development, and clinical research. The company has a strong international footprint with significant presence in Latin America, Africa, the USA, and other key markets. Q1 FY26 Earnings Summary Revenue: \u20b9510 crore, up 11.11% year-on-year YoY [&hellip;]<\/p>\n","protected":false},"author":1932,"featured_media":170966,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"jetpack_post_was_ever_published":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[105,392],"tags":[10162],"class_list":["post-170965","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-infographics","category-earnings","tag-pharmaceutical"],"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2025\/09\/CAPLI.png","jetpack_likes_enabled":false,"jetpack-related-posts":[{"id":169792,"url":"https:\/\/alphastreet.com\/india\/lupin-ltd-q1-fy26-earnings-results-51-rise-in-profits\/","url_meta":{"origin":170965,"position":0},"title":"Lupin Ltd Q1 FY26 Earnings Results &#8211; 51% rise in Profits","author":"Chirag Gupta","date":"August 6, 2025","format":false,"excerpt":"Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai. Lupin develops and commercializes a wide range of branded and generic formulations, biotechnology products, and APIs in over 100 markets in the U.S., India, South Africa, and across the Asia Pacific (APAC), Latin America (LATAM), Europe, and Middle East regions.\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"Lupin Q1 FY26 Earnings Results","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/1-4.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/1-4.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/1-4.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/1-4.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/1-4.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/1-4.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":157695,"url":"https:\/\/alphastreet.com\/india\/caplin-point-laboratories-navigating-successes-and-facing-challenges-in-pharmaceutical-expansion\/","url_meta":{"origin":170965,"position":1},"title":"Caplin Point Laboratories: Navigating Successes and Facing Challenges in Pharmaceutical Expansion.","author":"Divyansh_Kasana","date":"January 12, 2024","format":false,"excerpt":"Company Description: Caplin Point Laboratories, established in 1990, has evolved into a leading pharmaceutical company with a diverse product range, specializing in ointments, creams, and external applications. The company, a major player in generic formulations, holds over 4000 product licenses across 650 formulations globally. With a unique geographical focus on\u2026","rel":"","context":"In &quot;Research Summary&quot;","block_context":{"text":"Research Summary","link":"https:\/\/alphastreet.com\/india\/category\/research-summary\/"},"img":{"alt_text":"SHARDAMOTR Q1 FY26 Earnings Results","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/04\/iStock-1443507250.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/04\/iStock-1443507250.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/04\/iStock-1443507250.jpg?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/04\/iStock-1443507250.jpg?resize=700%2C400&ssl=1 2x"},"classes":[]},{"id":172213,"url":"https:\/\/alphastreet.com\/india\/lupin-q2-fy26-earnings-results\/","url_meta":{"origin":170965,"position":2},"title":"Lupin Q2 FY26 Earnings Results","author":"Chirag Gupta","date":"November 7, 2025","format":false,"excerpt":"Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai. Lupin develops and commercializes a wide range of branded and generic formulations, biotechnology products, and APIs in over 100 markets in the U.S., India, South Africa, and across the Asia Pacific (APAC), Latin America (LATAM), Europe, and Middle East regions.\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"Lupin Q2 FY26 Earnings Results","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/Lupin-Q2-FY26-Earnings-Results.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/Lupin-Q2-FY26-Earnings-Results.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/Lupin-Q2-FY26-Earnings-Results.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/Lupin-Q2-FY26-Earnings-Results.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/Lupin-Q2-FY26-Earnings-Results.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/Lupin-Q2-FY26-Earnings-Results.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":169548,"url":"https:\/\/alphastreet.com\/india\/strides-pharma-science-ltd-q1-fy26-earnings-results-97-fall-in-profits\/","url_meta":{"origin":170965,"position":3},"title":"Strides Pharma Science Ltd Q1 FY26 Earnings Results &#8211; 97% fall in Profits","author":"Chirag Gupta","date":"July 30, 2025","format":false,"excerpt":"Strides Pharma Science Ltd is in the business of development and manufacturing of pharmaceutical products. The company's pharmaceutical products are sold in over 100 countries. The company has always followed an inorganic growth strategy over the years that resulted in foray into new markets, addition of new business segments, therapy\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/3-13.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/3-13.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/3-13.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/3-13.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/3-13.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/3-13.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":169565,"url":"https:\/\/alphastreet.com\/india\/ajanta-pharma-ltd-q1-fy26-earnings-results-revenue-up-13-8-net-profit-up-3-7-yoy\/","url_meta":{"origin":170965,"position":4},"title":"Ajanta Pharma Ltd Q1 FY26 Earnings Results \u2013 Revenue Up 13.8%, Net Profit Up 3.7% YoY","author":"Divyansh_Kasana","date":"July 30, 2025","format":false,"excerpt":"Ajanta Pharma Limited is a specialty pharmaceutical company primarily engaged in the development, manufacturing, and marketing of high-quality finished dosage formulations. The company focuses on delivering innovative and affordable medicines across multiple therapeutic segments, strengthening its presence in domestic and international markets. Q1 FY26 Earnings Summary (Apr\u2013Jun 2025) Revenue: \u20b91,303\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/AJANTA.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/AJANTA.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/AJANTA.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/AJANTA.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/AJANTA.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/AJANTA.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":172210,"url":"https:\/\/alphastreet.com\/india\/caplin-point-q2-fy26-earnings-results\/","url_meta":{"origin":170965,"position":5},"title":"Caplin Point\u00a0Q2 FY26 Earnings Results","author":"Divyansh_Kasana","date":"November 7, 2025","format":false,"excerpt":"Caplin Point Laboratories Ltd, engaged in manufacturing and sourcing APIs, finished formulations, R&D, and clinical research with international presence across Latin America, Africa, USA, and other nations, delivered strong Q2FY26 financial results. Financial Highlights: Revenues rose 10.56% year-on-year to \u20b9534 crore from \u20b9483 crore. Total expenses grew 8.36% to \u20b9363\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"Q2 FY26","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/CAPLI.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/CAPLI.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/CAPLI.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/CAPLI.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/CAPLI.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/CAPLI.png?resize=1400%2C800&ssl=1 4x"},"classes":[]}],"jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/170965","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/users\/1932"}],"replies":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/comments?post=170965"}],"version-history":[{"count":0,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/170965\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/media\/170966"}],"wp:attachment":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/media?parent=170965"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/categories?post=170965"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/tags?post=170965"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}